New evidence suggests GLP-1 medications may do more than help people lose weight. Researchers are finding that these drugs could also directly protect the liver, offering new hope for people with metabolic liver disease.
According to CNN, a new study published in Cell Metabolism found that semaglutide - the active ingredient in Wegovy and Ozempic - improved liver health in mice even when weight loss did not occur. Scientists had long assumed the liver benefits of GLP-1 drugs mainly came from reduced body fat, but the new findings challenge that view.
The study focused on a small group of liver blood vessel cells known as liver sinusoidal endothelial cells. Researchers found these cells carry GLP-1 receptors and can respond directly to the drug. Once activated, they appeared to trigger anti-inflammatory signals that reduced liver damage and scarring.
This may help explain why some patients in earlier clinical trials showed better liver test results even when they lost little weight. Doctors say the findings could shift how treatment success is measured, especially for people who do not respond strongly to GLP-1 drugs in terms of weight reduction.
Experts caution that the latest research was done in mice, so more human studies are still needed. Still, the results add to growing evidence that GLP-1 medicines may provide broader health benefits, including reducing inflammation and supporting heart and kidney health.
